Valuation: Monopar Therapeutics Inc.

Market Cap 77Cr 67Cr 62Cr 57Cr 107.63Cr 7.33TCr 109.57Cr 733.46Cr 287.18Cr 3.64TCr 288.44Cr 282.12Cr 12TCr P/E 2026 *
-49.7x
P/E 2027 * -33.1x
Enterprise Value 65Cr 56Cr 52Cr 48Cr 91Cr 6.2TCr 93Cr 620.24Cr 242.85Cr 3.08TCr 243.91Cr 238.57Cr 10TCr EV / Sales 2026 *
-
EV / Sales 2027 * 41.4x
Free-Float
76.58%
Yield 2026 *
-
Yield 2027 * -
1 day-1.15%
1 week+3.16%
Current month+22.41%
1 month+19.27%
3 months+112.85%
6 months+73.09%
Current year+73.57%
1 week 104.97
Extreme 104.97
116.52
1 month 88.33
Extreme 88.33
116.64
Current year 50.07
Extreme 50.07
116.64
1 year 29.18
Extreme 29.18
116.64
3 years 1.37
Extreme 1.3695
116.64
5 years 1.37
Extreme 1.3695
116.64
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%+3.16%+175.23%+2,959.11% 77Cr
-0.28%+4.05%-0.31%+12.87% 4.94TCr
-1.26%+12.61%+26.06%+4.71% 3.91TCr
-2.27%+0.57%+410.63%+624.99% 4.09TCr
-2.20%-3.50%+4.44%+46.81% 3.58TCr
+5.56%+11.70%+11.64%+51.50% 3.05TCr
-2.00%-1.34% - - 1.66TCr
-0.55%-4.03%+35.09%+127.96% 1.61TCr
-0.20%-0.29%-2.31%-34.26% 1.28TCr
+0.29%+3.61%+2.20%+9.94% 1.37TCr
Average -0.39%+5.01%+73.63%+422.62% 2.56TCr
Weighted average by Cap. -0.38%+6.98%+79.46%+140.70%

Financials

2026 *2027 *
Net sales - 1.58Cr 1.38Cr 1.28Cr 1.18Cr 2.22Cr 151.23Cr 2.26Cr 15Cr 5.92Cr 75Cr 5.95Cr 5.82Cr 252.58Cr
Net income -2.02Cr -1.75Cr -1.63Cr -1.5Cr -2.83Cr -192.48Cr -2.88Cr -19Cr -7.54Cr -96Cr -7.57Cr -7.41Cr -321.47Cr -3.57Cr -3.1Cr -2.88Cr -2.66Cr -5.01Cr -341.18Cr -5.1Cr -34Cr -13Cr -169.45Cr -13Cr -13Cr -569.84Cr
Net Debt -12Cr -10Cr -9.56Cr -8.82Cr -17Cr -1.13TCr -17Cr -113.22Cr -44Cr -562.17Cr -45Cr -44Cr -1.89TCr -11Cr -9.76Cr -9.06Cr -8.36Cr -16Cr -1.07TCr -16Cr -107.27Cr -42Cr -532.65Cr -42Cr -41Cr -1.79TCr
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
31/26/31 $112.41 -1.96% 4,896
30/26/30 $114.66 +6.73% 3,27,068
29/26/29 $107.43 -1.53% 3,57,181
28/26/28 $109.09 -1.12% 5,28,971
27/26/27 $110.33 +0.42% 3,39,767
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
114.66USD
Average target price
116.85USD
Spread / Average Target
+1.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock